Arlington Trust’s Axcelis ACLS Stock Holding History

Arlington Trust’s Portfolio ACLS Stock Details ACLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10	Closed	-$1.3K	–	497
2023 Q4	$1.3K	Buy	+10	New	+$1.38K	﹤0.01%	768

Other funds holding ACLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arlington Trust's ACLS Position: Q1 2024 in Review

Arlington Trust sold out of Axcelis (ACLS) in Q1 2024, closing a stake of 10 shares — an estimated $1.3K sold.

Arlington Trust first reported a position in ACLS in Q4 2023 and held it in 1 quarter. The position peaked at $1.3K in Q4 2023. 385 funds tracked by Wall St. Rank hold ACLS as of Q1 2024.

Arlington Trust reported no remaining Axcelis position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 10 Axcelis shares in Q1 2024, an estimated $1.3K.
Arlington Trust first reported a position in Axcelis in Q4 2023 and held it in 1 quarter.
Arlington Trust's Axcelis position peaked at $1.3K in Q4 2023.
385 funds tracked by Wall St. Rank held Axcelis as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.